Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: Edison Investment Research
$10.00
Provider: Sadif Analytics Prime
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Orexo AB Announces Change of Chief Executive Officer and Chairman


Tuesday, 5 Feb 2013 02:00am EST 

Orexo AB announced the transition of its Chief Executive Officer (CEO), as the Company prepares for the anticipated United States (US) commercialization of its products, Zubsolv and Abstral. Mr. Nikolaj Sorensen, currently Chief Commercial Officer, will be promoted to CEO of the Company and Mr. Martin Nicklasson, currently Chairman of the Board, will be appointed Executive Chairman for an interim period of time, both effective as of February 5, 2013. Mr. Nikolaj Sorensen will succeed Mr. Anders Lundstrom, who will step down as CEO of the Company after two-year tenure. Mr. Nikolaj Sorensen joined Orexo AB in October 2011 and has focused the Company‚Äôs activities towards the business opportunities within the US opioid addiction market. Mr. Martin Nicklasson joined the Board of Orexo AB in April 2012 and has overseen the transformation of the Company from a technology focused Research and Development organization towards a fully integrated specialty pharmaceutical company. 

Company Quote

125.5
-2.25 -1.76%
4:13am EDT